Copyright
©2011 Baishideng Publishing Group Co.
World J Hepatol. Jan 27, 2011; 3(1): 24-30
Published online Jan 27, 2011. doi: 10.4254/wjh.v3.i1.24
Published online Jan 27, 2011. doi: 10.4254/wjh.v3.i1.24
Table 1 Distribution of hepatocellular carcinoma cases and control according to studied risk factors
| Risk factor | HCC cases (n = 164) | Controls (n = 250) | Odds ratio |
| NIDD | 18.00% (n = 139) | 2.70% (n = 225) | 8.0 (3.1 - 20.0) |
| HBV status | |||
| HBsAg +/anti-HBc + | 17.90% | 4.00% | 7.2 (3.2 - 16.1) |
| Anti-HBc + alone | 15.40% | 11.50% | 2.1 (1.1 - 4.0) |
| Anti-HBc +/anti-HBs + | 23.50% | 14.60% | 2.5 (1.5 - 4.4) |
| Anti-HCV | |||
| Anti-HCV + | 60.00% | 4.40% | 32.0 (15.8 - 65.0) |
Table 2 Risk of hepatocellular carcinoma related to hepatitis B virus and/or hepatitis C virus infections and non-insulin-dependent diabetes
| Risk factor | Adjusted odds ratio | 95% IC |
| NIDD | 5.9 | 1.7 - 19.7 |
| HBsAg +/anti-HBc + | 10.6 | 3.9 - 28.8 |
| Anti-HCV + | 33.3 | 14.1 - 78.8 |
| B/C co-infection | 84.7 | 4.3 - 366.9 |
Table 3 Prevalence of viral markers and non-insulin-dependent diabetes in hepatocellular carcinoma patients with cirrhosis
| Presence of cirrhosis (n = 108) | Absence of cirrhosis (n = 25) | P | |
| Anti-HCV positive | 51 | 5 | 0.01 |
| HbsAg positive | 12 | 2 | 0.48 |
| HBV and HCV | 6 | 1 | 0.60 |
| Presence of NIDD | |||
| NIDD alone | 2 | 0 | 0.81 |
| HCV and NIDD | 16 | 1 | 0.12 |
| HBV and NIDD | 2 | 1 | 0.46 |
| HBV, HCV and NIDD | 1 | 1 | 0.34 |
| Negative for HBV, HCV and NIDD | 19 | 14 | < 10-3 |
- Citation: Bahri O, Ezzikouri S, Alaya-Bouafif NB, Iguer F, Feydi AEE, Mestiri H, Benazzouz M, Khalfallah T, Afifi R, Elkihal L, Berkane S, Marchio A, Debzi N, Dejean A, Pineau P, Triki H, Benjelloun S. First multicenter study for risk factors for hepatocellular carcinoma development in North Africa. World J Hepatol 2011; 3(1): 24-30
- URL: https://www.wjgnet.com/1948-5182/full/v3/i1/24.htm
- DOI: https://dx.doi.org/10.4254/wjh.v3.i1.24